• Tuhura Biosciences received U.S. Patent No. 12,734,168 covering use of delta opioid receptor antagonists in cancers linked to DOR-expressing MDSCs.
• Claims cover combination approaches aimed at reducing immunosuppressive myelopoiesis to improve responses to immunotherapy.
• Patent also describes use beyond antibody-drug conjugates, including adoptive cell therapies such as CAR-T, Tregs, TILs.
• Issued Sept. 15, 2026; stated patent term runs through 2043 before any potential extension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050745PR_NEWS_USPR_____LA63162) on October 05, 2026, and is solely responsible for the information contained therein.